程序性细胞死亡
生物
细胞生物学
计算生物学
细胞凋亡
遗传学
作者
Logan B. Leak,Ziwei Wang,Alby J. Joseph,Brianna Johnson,Alyssa A. Chan,Cassandra M. Decosto,Leslie Magtanong,Pin‐Joe Ko,Weaverly Colleen Lee,Joan Ritho,Sophia Manukian,Alec Millner,Shweta Chitkara,Jennifer J. Salinas,Rachid Skouta,Matthew G. Rees,Melissa M. Ronan,Jennifer A. Roth,Chad L. Myers,Jason Moffat
标识
DOI:10.1038/s41589-025-01913-4
摘要
Abstract Small molecules that induce non-apoptotic cell death are of fundamental mechanistic interest and may be useful to treat certain cancers. Here, we report that tegavivint, a drug candidate undergoing human clinical trials, can activate a unique mechanism of non-apoptotic cell death in sarcomas and other cancer cells. This lethal mechanism is distinct from ferroptosis, necroptosis and pyroptosis and requires the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR). TECR is canonically involved in the synthesis of very long chain fatty acids but appears to promote non-apoptotic cell death in response to CIL56 and tegavivint via the synthesis of the saturated long-chain fatty acid palmitate. These findings outline a lipid-dependent non-apoptotic cell death mechanism that can be induced by a drug candidate currently being tested in humans.
科研通智能强力驱动
Strongly Powered by AbleSci AI